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Abstract
Background: Kidney transplant recipients often receive large volumes of intravenous fluid replacement in the peri-
operative period. Administration of 0.9% saline has previously been associated with acidosis, hyperkalaemia and acute
kidney injury. The perioperative use of physiologically balanced replacement fluids may reduce the incidence of post-
operative renal replacement therapy and hyperkalaemia.
Methods: A retrospective review of consecutive renal transplants before and after a change in perioperative fluid prescrip-
tion from 0.9% saline to Plasma-Lyte 148.
Results: A total of 97 patients were included in the study, 59 receiving exclusively 0.9% saline and 38 receiving exclusively
Plasma-Lyte. Patients in the Plasma-Lyte group were less likely to require emergency postoperative dialysis than those receiving
0.9% saline [odds ratio (OR) 0.15 (95% confidence interval 0.03–0.48), P¼0.004], and these patients had more favourable biochemi-
cal parameters with less hyperkalaemia, less acidosis and better diuresis. Patients in the Plasma-Lyte group also had a shorter
length of hospital stay (7 days versus 11 days; P<0.0001) and better graft function at 3 months postoperatively (estimated glo-
merular filtration rate 51 versus 44 mL/min/1.73 m2; P¼0.03); however, there was no difference in graft function at 1 year.
Conclusions: Plasma-Lyte in the perioperative period is safe in renal transplantation and is associated with a favourable
biochemical profile, including a reduced incidence of hyperkalaemia, better diuresis and less frequent use of renal replace-
ment therapy early after surgery. In patients receiving Plasma-Lyte, graft function was better at 3 months, but this differ-
ence did not persist up to 1 year after transplantation.
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Kidney transplantation is the treatment of choice for patients
with end-stage renal disease. A scarcity of organs heightens the
need to focus on providing the best possible outcome at every
stage of the transplantation process [1].
While there are many determinants of long-term graft out-
come after renal transplantation, patient variables in the peri-
operative period, such as cold ischaemia time, mean arterial
pressure, early urine output and fluid balance, are of impor-
tance and they have been shown to have significant influence
on long-term as well as short-term graft function [2–6].
Some degree of ischaemic allograft injury is inevitable dur-
ing renal transplantation; however, severe injury leading to
delayed graft function may require early renal replacement
therapy (RRT). Delayed graft function has an independent effect
on short- and long-term allograft survival, regardless of donor
quality [3]. Furthermore, there is growing evidence from the
non-transplant acute kidney injury (AKI) literature suggesting
that haemodynamic instability associated with intermittent
haemodialysis (commonly administered to patients with
delayed graft function in kidney transplant centres), as opposed
to continuous RRT, may prolong AKI and worsen long-term
renal outcomes [4, 5].
As well as maintaining appropriate fluid volume, the choice
of fluid may also influence renal outcomes. A 0.9% saline solu-
tion remains the most widely used intravenous fluid during the
perioperative period, but recent data has emerged questioning
its safety [6–8]. A 0.9% saline solution has been shown to reduce
renal cortical blood flow in healthy volunteers [9], and animal
studies have suggested that sustained renal vasoconstriction is
specifically related to hyperchloraemia [10]. The high chloride
load in 0.9% saline has also been shown to induce hyperchlorae-
mic acidosis [11], and this in turn has been associated with the
development and accentuation of postoperative AKI [12].
Plasma-Lyte is a balanced crystalloid solution that closely
resembles the composition of human plasma (Table 1). There is
a paucity of data assessing the impact of Plasma-Lyte on renal
function in patients who are undergoing renal transplantation,
thus the European Renal Best Practice (ERBP) transplantation
guidelines [13] and the Kidney Disease: Improving Global
Outcomes (KDIGO) transplantation guidelines [14] recommend
using 0.9% saline during transplantation.
A change in the intra-operative fluid regimen from 0.9%
saline to Plasma-Lyte was implemented in our hospital in
response to increasing evidence and national guidance regard-
ing general fluid management of patients undergoing major
surgery [15]. This change was also implemented for renal trans-
plant recipients in our centre and extended to include the
immediate postoperative period.
We hypothesized that the use of Plasma-Lyte in the
perioperative period of renal transplantation would result in a
reduction in the need for early RRT and fewer episodes of hyper-
kalaemia in the early postoperative period. As secondary end-
points, we examined plasma biochemical parameters and urine
output, biopsy-proven rejection by 3 months and improved
early graft function at 3 months and 1 year after surgery.
Materials and methods
Ethics
Approval for this study was as a retrospective review of data in
the form of audit of clinical practice.
Study design
An observational retrospective study was performed in a single
large renal transplant centre. A hospital-wide change in intra-
operative fluid regimen from 0.9% saline to Plasma-Lyte was
implemented in January 2013, which was extended to cover the
routine postoperative period in renal transplant patients. We
included consecutive renal transplants in the 6 months prior to
the policy change, then following a 6-month transition period,
consecutive renal transplants for further 6 months. Patients
were excluded if their inpatient notes were unavailable or if the
fluid administered did not comply with the policy at the time
(including the use of sodium bicarbonate solution). This study is
thus a per-protocol analysis.
Electrolytes, the need for RRT and the volume and composi-
tion of intravenous fluid administered were documented from
paper and electronic inpatient medical records. Renal function
at 3 months and at 1 year post-surgery was recorded.
Patients in both cohorts were managed postoperatively on
either an acute renal ward or a renal high-dependency unit.
There were no changes in management policy between the care
given to the two cohorts of patients other than the switch from
0.9% saline to Plasma-Lyte. In both cohorts, the rate of fluid
administration, decisions regarding RRT, inpatient biopsy and
discharge from hospital were recorded by the responsible con-
sultant from a highly experienced pool of clinicians who did not
change throughout the study. Any patient who had a pre-
operative potassium >6.0 mmol underwent dialysis prior to
transplantation. All patients had blood tests preoperatively,
postoperatively on recovery and at 7 a.m. each day thereafter,
unless additional tests were clinically indicated. All patients
underwent protocol transplant biopsy at 3 months unless this
was deemed unsuitable or unnecessary based on individual
patient characteristics.
Statistical methods
Statistical analysis was done using R (R Development Core
Team, R Foundation for Statistical Computing, Vienna, Austria;
http://www.R-project.org).
We sought to assess the effect of the choice of fluid therapy
in the perioperative period on the probability of needing RRT
within 48 h of renal transplantation. To exclude the effect of
potential confounders we performed a multivariable logistic
regression including the following clinically plausible variables:
preoperative potassium, modality of RRT prior to transplanta-
tion (none, i.e. pre-emptive transplantation; haemodialysis or
peritoneal dialysis), donor type (live donor, donation after brain
death (DBD) or donation after cardiac death (DCD)), cold ischae-
mia time>12 h (live donors were imputed a cold ischaemia time
<12h), age and sex. Forward and backward selection based on
Table 1. Composition of intravenous fluids [1, 3]
Strong ion (mmol/L) 0.9% saline Plasma-Lyte
Sodium (Naþ) 154 140
Chloride (Cl) 154 98
Potassium (Kþ) 0 5
Calcium (Ca2þ) 0 0




2 | A. Adwaney et al.
minimization of Akaike’s Information Criterion (AIC) was used
to develop the final model.
Time free from RRT, for delayed graft function in the first 5
days after surgery, was plotted as a Kaplan–Meier estimator and
compared using the log-rank test for days after transplantation.
Patients who needed RRT after early graft loss for surgical rea-
sons necessitating graft nephrectomy were censored from this
analysis. Comparisons in biochemical characteristics, such as




A total of 97 patients were included in the study (Figure 1); 59
received exclusively 0.9% saline and 38 received exclusively
Plasma-Lyte. Baseline demographics and details of transplanta-
tion are shown in Table 2. There were no significant differences
between the two groups: 6/59 (10%) patients in the 0.9% saline
group and 3/38 (7.8%) in the Plasma-Lyte group had RRT in the
preceding 24 h of transplantation due to either hyperkalaemia
or scheduled outpatient dialysis. All patients who received RRT
in the pre- or postoperative period underwent intermittent
haemodialysis.
Primary objective: early postoperative RRT
We excluded two patients from this analysis who suffered
immediate surgical complications requiring graft nephrectomy
(one renal vein and one renal artery thrombosis; both patients
were in the 0.9% saline group). At least one episode of RRT in
the first 5 days postoperatively was required in 20/57 (35%)
patients in the 0.9% saline group compared with 9/38 (24%)
patients in the Plasma-Lyte group. The absolute risk reduction
was 0.11 [95% confidence interval (CI) 0.07 to 0.28; P¼ 0.36],
which although not statistically significant, does suggest a
trend in favour of the Plasma-Lyte group. All patients who
required RRT had hyperkalemia: three patients in the 0.9%
saline group and one patient in the Plasma-Lyte group, who
also had respiratory compromising pulmonary oedema.
However, there was significantly more RRT within the first and
second 24 h postoperatively in the 0.9% saline group (Figure 2).
A simplistic comparison between those that did and did not
receive RRT within the first 48 h suggests RRT is associated with
patients who received 0.9% saline, were older and had a donor
following circulatory death (Table 3). A logistic regression analy-
sis was then performed to explore whether these between-
group differences in donor and recipient characteristics were
confounding our assessment of the effect of perioperative fluid
type on the need for RRT in the first 48 h following renal trans-
plant (Table 4).
After accounting for these important clinical variables, the
use of Plasma-Lyte was strongly associated with a decreased
need for dialysis in the first 48 h after surgery, with an OR of
Fig. 1. Study recruitment chart.






Male, n (%) 45 (76) 24 (66) 0.17
Age (years) 49 (20–70) 46 (18–73)0.43
Ethnicity, n (%)
White 29 (49) 21 (55) 0.67
Black 13 (22) 6 (16) 0.60
South Asian 14 (24) 10 (26) 0.64
Other 3 (5) 1 (3) 0.36
Time on RRTa (years) 4 (1–25) 3 (1–31) 0.63
RRT mode prior to transplant, n (%)
Pre-emptive 6 (10) 7 (18) 0.36
Haemodialysis 44 (75) 25 (66) 0.37
Peritoneal dialysis 9 (15) 6 (16) 1
Donor age (years) 52 (19–70) 55 (19–71)0.41
Donor type, n (%)
Live related 15 (25) 7 (18) 0.47
Live unrelated 6 (10) 3 (8) 0.4
Live combined, n (%) 21 (35) 10 (26) 0.38
Donation after brain death, n (%) 21 (36) 22 (58) 0.24
Donation after circulatory death, n (%)17 (29) 6 (16) 0.22
ABO incompatible, n (%) 6 (10) 3 (8) 1
Cold ischaemia timeb (h) 14 (8–17) 14 (12–19)1
Results are presented as median and range unless stated otherwise.
aIncludes previous renal transplant.
bFor donors after brain death and donors after cardiac death only.
Fig. 2. Kaplan–Meier plot showing the chance of remaining free from renal
replacement therapy in the first 5 days post-transplantation, censored for oper-
ative complications causing immediate graft failure.
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0.15 (95% CI 0.03–0.48; P¼ 0.004). The only other variable signifi-
cantly associated with the risk of early RRT once accounting for
the type of fluid administered was cold ischaemia time.
Secondary objectives
Plasma biochemistry
Patients in the Plasma-Lyte group had lower serum potassium
and chloride levels postoperatively (despite identical pre-
operative values) and had higher levels of serum bicarbonate
(our routine chemistry panel omits bicarbonate, hence the lack
of preoperative values), as shown in Figure 3A and 3B. We sub-
sequently assessed the incidence of moderate to severe hyper-
kalaemia (serum potassium>6.0 mmol/L). All patients were
included in the analysis up to the point they received RRT.
Perioperative use of Plasma-Lyte was significantly associ-
ated with a reduced incidence of postoperative hyperkalaemia
in the immediate postoperative period (10/57 versus 1/38 in the
0.9% saline and Plasma-Lyte groups, respectively; P¼ 0.045).
Fluid balance
Patients in the Plasma-Lyte group had a higher urine output than
those in the 0.9% saline group (Figure 3C). The improved diuresis
was associated with an increase in fluid volume administration,
but there was no difference in daily fluid balance (Figure 3D).
Long-term outcomes
In the first year after transplantation there were three deaths in
the 0.9% saline group (two from sepsis, one complication follow-
ing kidney biopsy), compared with one death in the Plasma-
Lyte group (sepsis). Length of hospital stay was significantly
shorter in the Plasma-Lyte group, at a median of 7 days (range
5–25), compared with 11 days in the 0.9% saline group (range 5–
55; P< 0.0001; Mann–Whitney U test). After removing three out-
liers from the 0.9% saline group with lengths of stay of 55, 35
and 33 days, the length of stay remained significantly longer in
the 0.9% saline group [median length of stay 11 days (range
5–30), P¼ 0.0007]. Of those discharged from the hospital with
functioning grafts, there were two graft failures at 3 months
post-transplant and another by 12 months in the 0.9% saline
group, compared with one graft failure by 3 months and another
by 12 months in the Plasma-Lyte group.
There were fewer biopsies carried out in the Plasma-Lyte
group during the inpatient period following transplantation
(13.1% versus 30.1%; P¼ 0.055) and they demonstrated less
rejection (2.63% versus 18.6%; P¼ 0.02). A similar proportion in
the Plasma-Lyte and 0.9% saline groups had a protocol biopsy
carried out at 3 months (59.3% versus 57.8%) and the rates of
rejection were 13.1% versus 28.8% (P¼ 0.08), respectively.
Three months following transplantation there was a signifi-
cant difference in estimated glomerular filtration rate (eGFR)
between the two groups (44 versus 51 mL/min in the 0.9% saline
and Plasma-Lyte groups, respectively; P¼ 0.03). However, there
was no difference in eGFR at 1 year (Figure 3E).
Discussion
The use of Plasma-Lyte during the perioperative period of renal
transplantation is safe and is associated with a reduction in the
need for dialysis and a reduced incidence of hyperkalaemia in
the immediate postoperative period when compared with 0.9%
saline. The Plasma-Lyte group demonstrates more physiological
biochemistry and greater postoperative diuresis; hence we
observed a higher fluid volume administration compared with
the 0.9% saline group while the total fluid balance of each group
remained essentially the same. Although there is no difference
in renal function at 1-year post-transplant, the Plasma-Lyte
group reached a significantly better eGFR at 3 months, with
biopsy results suggesting there may be less early rejection com-
pared with the 0.9% saline group.
This is the first study in renal transplant recipients comparing
Plasma-Lyte to 0.9% saline use throughout the perioperative
period of renal transplantation and to include information
regarding outcomes at 3 months and 1 year. The significant
reduction in the need for dialysis in the first 48 h postoperatively
is related to the use of Plasma-Lyte, as is the reduction in inci-
dence of hyperkalaemia. There is an ongoing trend for less dialy-
sis after 48 h, and this is important as haemodynamic changes
and risks associated with anticoagulation decrease as the time
from surgery increases.
A 2016 Cochrane summary of studies that compared 0.9%
saline with balanced crystalloid solutions during renal transplant
surgery supports our findings [16]. O’Malley et al. [17] gave either
lactated Ringer’s solution or 0.9% saline during anaesthesia to
patients undergoing renal transplantation followed by dextrose
and bicarbonate postoperatively. This study was stopped early,
as there was a significant reduction in hyperkalaemia immedi-
ately post-transplantation in the Ringer’s lactate group. A subse-
quent study compared the use of Ringer’s lactate, Plasma-Lyte
and 0.9% saline during surgery [18]. After 90 min there was a
Table 3. A comparison of the binary variables used in logistic regres-
sion for patients who received RRT in the first 48 h compared with
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Cold ischaemia time (h),
median (range)
13 (0–18) 10 (0–21) 0.09
Recipient age (years),
median (range)
56 (20–64) 46 (18–70) 0.005
Pre-transplant mode of RRT, n (%)
Haemodialysis 16 (76) 51 (68) 0.59
Peritoneal dialysis 4 (19) 11 (16) 0.73
Pre-emptive 1 (5) 13 (17) 0.29
Donor type, n (%)
Live related 2 (10) 20 (26) 0.14
Live unrelated 2 (10) 7 (9) 1
Donation after
brain death
8 (38) 34 (45) 0.6
Donation after
circulatory death
9 (42) 14 (19) 0.04
Table 4. Multivariable logistic regression analysis of the need for
renal replacement therapy in the first 48 h after transplantation
Variable OR 2.5% 97.5% P-value
Plasma-Lyte versus 0.9% saline 0.14 0.03 0.48 0.004
Cold ischaemia time (h) 3.12 1.06 9.78 0.04
Recipient age (years) 1.05 1.00 1.11 0.053
Preoperative potassium 1.41 0.84 2.44 0.2
4 | A. Adwaney et al.
statistically significant increase in chloride with a decrease in pH
and base excess in the 0.9% saline group. These changes did not
persist in the postoperative period, when fluid therapy was the
same in all patients (dextrose saline).
A key feature of our study compared with others is the
extension of Plasma-Lyte use into the postoperative period. The
likely beneficial effects seen in the Plasma-Lyte group (better
diuresis, improved potassium and acid base homeostasis,
reduced incidence of early RRT) may be most pronounced as
volumes of fluid administration are at their highest (frequently
8–10 L in 24 h in our study). The evidence that high-volume
chloride administration effects renal blood flow [13], which in
turn has been suggested as the cause for an increased preva-
lence of AKI and the need for RRT in critically ill patients [22,
23], may be an important factor in our study. However, the asso-
ciation between the development and accentuation of AKI and
0.9% saline administration in critically ill patients remains con-
troversial, with data both supporting and rejecting the hypothe-
sis [19, 20]. A recent study failed to demonstrate a benefit of
Plasma-Lyte on the incidence of AKI, but the mean fluid volume
administered was only 2 L in 24 h, considerably less than in our
study [10].
There is an association between sodium intake and inflam-
mation in both human and animal models [21–28]. There is also
an increasing understanding that inflammation may precipitate
or enhance rejection, and this provides a biologically plausible
explanation for a reduced incidence of rejection and improved
eGFR at 3 months in the Plasma-Lyte group [29]. However, this
may be a chance finding and needs considerably more investi-
gation, though delayed graft function and the need for
postoperative dialysis is a risk factor for rejection [30].
The strengths of this study are the inclusion of consecutive
transplants looked after by the same group of specialty consul-
tants with all decisions regarding RRT made by the senior neph-
rologist. The rate of missing data is low and deviation from the
fluid administration protocol was also low. However, the study
was not randomized and is limited to one transplant centre.
Our sample size is not large enough to address our hypothesis
with certainty. We recognize the difference in sample size
between both groups; patients in the Plasma-Lyte group were
excluded because they did not exclusively receive Plasma-Lyte
intra-operatively, despite leaving a washout period between
both periods studied. We also excluded patients who did not
have complete notes from both groups, which may have led to
some selection bias. Despite the two groups being well
matched, it is possible that other factors in patient manage-
ment between the two periods studied may have accounted for
some of the differences in clinical outcomes. While we accept
the 0.9% saline group had a greater number of donors after car-
diac death compared with the Plasma-Lyte group, there were
Fig. 3. Changes in potassium, chloride, bicarbonate, associated fluid volume administration and urine output with fluid balance censored for the need for dialysis.
(A) Kruskal–Wallis analysis of variance for 0.9% saline versus Plasma-Lyte over time; serum chloride P<0.0001 and serum potassium P¼ 0.002. (B) Significant differen-
ces between 0.9% saline and Plasma-Lyte for serum bicarbonate levels; P¼0.0014, P¼0.045 and P¼0.0003, respectively, at each time point after transplantation. (C)
More fluid was administered in the Plasma-Lyte group both during surgery (P¼0.005) and in the first 24 h (P¼0.003) and this was in line with significantly more urine
output (P¼0.04) in the first 24 h, but neither parameter was statistically different at 48 h after transplantation. (D) The daily fluid balance was no different between the
two groups on each day. (E) The eGFR was significantly higher at 3 months in the Plasma-Lyte group compared with the 0.9% saline group (P¼0.03), but by 1 year there
was no difference.
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more donors after brain death and fewer live donors in the
Plasma-Lyte group. Multivariable logistic regression analysis
does not show donor type affecting the primary outcome. Very
close to the time of transition, a renal high dependency unit
was opened where most of the Plasma-Lyte group were cared
for. The improved nursing skill mix may have had an influence
on outcomes in the Plasma-Lyte group compared with the 0.9%
saline group, who were managed in a specialized area of the
acute renal ward. All patients were looked after by the same
clinicians during both periods studied. Recipients in both
groups had potassium levels measured immediately
postoperatively on recovery, when arriving in the ward and at
7 a.m. each day thereafter. Fluid balance and administration
was accurately recorded in all patients included in the study.
In summary, the use of Plasma-Lyte in the perioperative
period of kidney transplantation reduces the need for RRT in
the immediate postoperative period and improves plasma bio-
chemistry. There is a suggestion that there is better early graft
function and a reduction in the number of rejection episodes.
The administration of large volumes of 0.9% saline represents a
physiologically abnormal load of sodium and chloride, so it is
biologically plausible that balanced solutions may lessen this
metabolic insult. Switching to Plasma-Lyte offers a relatively
cheap and easy intervention that contributes to improvements
in the perioperative care of renal transplant patients.
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